EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR
Frontiers in Allergy,
Год журнала:
2025,
Номер
5
Опубликована: Фев. 3, 2025
Allergic
rhinitis
(AR),
the
most
prevalent
immunological
disease,
affects
approximately
400
million
individuals
globally
and
can
significantly
impact
quality
of
life
(QoL).
Despite
nearly
25
years
guidelines,
AR
remains
largely
under-
diagnosed,
suboptimally
treated
poorly
controlled.
In
light
new
knowledge
treatment
options,
there
is
a
necessity
to
update
or
revise
fundamental
definitions
facilitate
communication
across
diverse
specialties
engaged
in
its
improve
patient
care.
The
European
Forum
for
Research
Education
Allergy
Airway
Diseases
(EUFOREA)
convened
meeting
experts
representatives
deliberate
optimal
methodology
measuring
responses
establishing
novel
goals.
This
paper
presents
consensus
on
revised
definitions,
including
control,
severe
allergic
rhinoconjunctivitis
(SARC),
refractory
(R-SARC),
remission,
resolution,
improvement,
exacerbation,
treatable
traits
(TTs),
treat
target,
relapse,
progression,
disease
modification,
prevention.
Язык: Английский
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024
Frontiers in Allergy,
Год журнала:
2025,
Номер
6
Опубликована: Фев. 24, 2025
In
April
2024,
the
European
Summit
"Raising
bar
in
respiratory
care"
was
organized
by
Forum
for
Research
and
Education
Allergy
Airway
Diseases
(EUFOREA)
Parliament
hosted
Members
of
Dorien
Rookmaker
Mislav
Kolakušić.
The
aim
to
respond
need
patients
suffering
from
chronic
diseases
(CRDs)
joining
forces
with
global
organisations
management
epidemics
CRD,
recognising
weaknesses
current
care
models
focussing
on
collaboration
improve
prevention.
Participants
belonging
International
National
Societies
Committees
Rhinologic
Society
(ERS),
(IRS),
Belgian
Respiratory
(BeRS),
Global
Initiative
Asthma
(GINA),
Chronic
Obstructive
Lung
Disease
(GOLD),
Alliance
against
(GARD),
Federation
Airways
Patients
Associations
(EFA)
EUFOREA's
Patient
Advisory
Board
(PAB)
described
their
vision
action
plan
work
partnership
raise
care.
This
report
summarizes
contributions
representatives
different
stakeholders
field
CRDs.
Язык: Английский
EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus
Pediatric Allergy and Immunology,
Год журнала:
2024,
Номер
35(7)
Опубликована: Июль 1, 2024
Abstract
The
European
Forum
for
Research
and
Education
in
Allergy
Airways
diseases
(EUFOREA)
organized
its
bi‐annual
forum
EUFOREUM
Berlin
November
2023.
aim
of
2023
was
to
highlight
pediatric
action
plans
prevention
optimizing
care
type
2
inflammatory
conditions
starting
childhood,
with
a
focus
on
early‐stage
diagnosis,
ensuring
neither
under‐
nor
overdiagnosis,
optimal
care,
suggestions
improvement
care.
EUFOREA
is
an
international
not‐for‐profit
organization
forming
alliance
all
stakeholders
dedicated
reducing
the
prevalence
burden
chronic
respiratory
through
implementation
patient
via
educational,
research,
advocacy
activities.
inclusive
multidisciplinary
approach
reflected
keynote
lectures
faculty
virtual
(
www.euforea.eu/euforeum
)
coming
from
pediatric,
allergology,
pulmonology,
ENT,
dermatology,
primary
health
fields
patients
around
central
theme
inflammation.
As
most
may
start
childhood
or
adolescence,
children
have
inflammation
when
suffering
skin
disease,
moment
has
come
raise
bar
ambitions
including
prevention,
remission
disease
modification
at
early
stage.
current
report
provides
comprehensive
overview
key
statements
by
allowing
field
be
updated
ready
join
forces
Europe
beyond.
image
Язык: Английский
Allergen Immunotherapy for the Prevention and Treatment of Asthma
Clinical & Experimental Allergy,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 4, 2024
Allergic
asthma
is
the
predominant
phenotype
among
asthmatics.
Although
conventional
pharmacotherapy
a
central
component
in
management
of
asthma,
it
does
not
enable
control
symptoms
all
patients.
In
recent
decades,
some
uncontrolled
asthmatic
patients,
especially
those
with
allergic
have
benefited
from
biological
therapies.
However,
biologics
do
address
unmet
needs
left
by
pharmacotherapy.
Furthermore,
noteworthy
that
neither
nor
therapies
disease-modifying
properties.
this
context,
allergen
immunotherapy
(AIT)
represents
an
indispensable
therapeutic
arsenal
against
due
to
its
immunological
effects.
review
article,
funded
AIT
manufacturer,
we
find
clinical
trials
support
as
only
treatment
option
able
both
improve
and
prevent
onset
worsening
condition.
For
patients
severe
or
other
safety
concerns,
combination
offers
very
promising
new
modalities
for
asthma.
Trial
Registration:
clinicaltrials.gov
identifier:
NCT06027073.
Язык: Английский
European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned
Frontiers in Allergy,
Год журнала:
2024,
Номер
5
Опубликована: Дек. 12, 2024
The
European
Forum
for
Research
and
Education
in
Allergy
Airways
diseases
(EUFOREA)
organized
the
first
Biologic
Training
Course
(EBTC)
Brussels
on
1st
March
2024.
aim
of
this
hybrid
EBTC
including
both
face-to-face
web-based
participation
was
to
address
educational
needs
physicians
dealing
with
asthma
Chronic
Rhinosinusitis
Nasal
Polyps
(CRSwNP)
clinically
relevant
aspects
diagnosing
treatment
biologics.
EUFOREA
is
an
international
non-for-profit
organization
forming
alliance
all
stakeholders
dedicated
reducing
prevalence
burden
chronic
respiratory
through
implementation
optimal
patient
care
via
educational,
research,
advocacy
activities.
inclusive
multidisciplinary
approach
reflected
faculty
coming
from
paediatric,
allergology,
pulmonology,
Ear,
Nose
Throat
(ENT)
speciality
different
continents,
more
than
250
participants
over
30
countries
EBTC.
current
report
provides
a
comprehensive
overview
key
statements
made
by
2024,
especially
focusing
selection
biologic
drug,
communication
patients,
onset
biological
follow-up
routine
clinical
practice.
Язык: Английский